AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16006194
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (1 g eicosapentaenoic acid (EPA) and 0.7 g docosahexaenoic acid (DHA) daily)
Trial: 8725038
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg BCG therapy
Trial: 8725038
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg BCG therapy
Trial: 352142
Drug: Duck Embryo
RxNorm normalized name: Duck
DrugBank: Duck (DB10610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duck Embryo Vaccine (DEV), 4 doses
Trial: 352142
Drug: WI-38 Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WI-38 Vaccine (WRV), 4 doses
Trial: 352142
Drug: WI-38 Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WI-38 Vaccine (WRV), 2 doses
Trial: 352142
Drug: WI-38 Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WI-38 Vaccine (WRV), 3 or 4 doses
Trial: 31029515
Drug: 10-10-PLAIN (non-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-10-PLAIN (non-adjuvanted formulation)
Trial: 31029515
Drug: 10-10-AS01 (AS01-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-10-AS01 (AS01-adjuvanted formulation with 10 µg of each antigen)
Trial: 31029515
Drug: 10-3-AS01 (AS01-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-3-AS01 (AS01-adjuvanted formulation with 10 µg of each NTHi antigen and 3.3 µg of Mcat antigen)
Trial: 26488693
Drug: Nicotinamide 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide 500 mg twice daily
Trial: 17077229
Drug: CDB‐2914 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDB‐2914 (50 mg single dose)
Trial: 17077229
Drug: Levonorgestrel (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (0.75 mg two doses taken 12 hours apart)
Trial: 15039761
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release d‐amphetamine (escalating 15‐30 or 30‐60 mg)
Trial: 15039761
Drug: Risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2 or 4 mg)
Trial: 9097530
Drug: Ivermectin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (100 micrograms/kg, two single doses, 3 months apart)
Trial: 26386381
Drug: Honey based
RxNorm normalized name: honey based topical applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey based formulation of Nigella sativa seed oil (5 ml N. sativa oil orally daily) for 8 weeks
Trial: 23000726
Drug: Tulobuterol patches
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol patches (1-2mg daily)
Trial: 23000726
Drug: Theophylline (4-5mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (4-5mg/kg daily)
Trial: 19087899
Drug: TSD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSD and paroxetine treatment
Trial: 19087899
Drug: TSD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSD and 2 weeks of placebo followed by paroxetine treatment
Trial: 19087899
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of paroxetine treatment
Trial: 15330779
Drug: Outdoor air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outdoor air supply rate at 10 l/s/p and temperature at 24.5 degrees C
Trial: 15330779
Drug: Outdoor air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outdoor air supply rate at 5 l/s/p and temperature at 22.5 degrees C
Trial: 15330779
Drug: Outdoor air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outdoor air supply rate at 5 l/s/p and temperature at 24.5 degrees C
Trial: 15330779
Drug: Temperature reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temperature reduction from 24.5 degrees C to 22.5 degrees C at 10 l/s/p
Trial: 11094581
Drug: Amiodarone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (900 mg per 24 h)
Trial: 11094581
Drug: Magnesium (4
RxNorm normalized name: magnesium oxide 265.3 mg magnesium (440 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (4 g per 24 h)
Trial: 11094581
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl; 50 ml per 24 h)
Trial: 8833058
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (MTX 17.5 mg/week, sulfasalazine 500 mg bid, hydroxychloroquine 200 mg bid)
Trial: 8833058
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxychloroquine and sulfasalazine
Trial: 1430130
Drug: Gonadotrophin releasing
RxNorm normalized name: Gonadotrophin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin releasing hormone agonist (GnRHa) in the midluteal phase coupled with follicular phase administration of human menopausal gonadotrophin
Trial: 3908501
Drug: carteolol 5
RxNorm normalized name: CARTEOLOL 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carteolol 5 mg
Trial: 3908501
Drug: carteolol 20
RxNorm normalized name: carteolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carteolol 20 mg
Trial: 31751183
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg bid)
Trial: 28741804
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein group (1.2 g/kg per day protein diet + 25% additional whey protein supplement)
Trial: 28741804
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1.2 g/kg per day protein diet without additional whey protein supplementation)
Trial: 23130909
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (400 mg) plus folic acid (600 µg)
Trial: 23130909
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (ferrous sulfate with folic acid)
Trial: 23130909
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous iron and oral iron
Trial: 17133559
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg) with methotrexate
Trial: 14535876
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Trial: 14535876
Drug: Antimicrobial sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial sensitivity testing-based treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Trial: 14535876
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg b.d., clarithromycin, 500 mg b.d., and amoxicillin, 1 g b.d.
Trial: 14535876
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Trial: 10746516
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg magnesium + 50 mg vitamin B6
Trial: 9545899
Drug: 0.06% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06% chlorhexidine irrigation using a powered oral irrigator (Water Pik)
Trial: 9545899
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate rinsing once daily
Trial: 1408551
Drug: Planned bottle
RxNorm normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned bottle group (one bottle daily between the second and sixth weeks postpartum)
Trial: 30528222
Drug: Cabozantinib 60mg
RxNorm normalized name: CABOZANTINIB 60MG TAB
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib 60mg once daily orally
Trial: 30528222
Drug: Mitoxantrone 12mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12mg/m2 every 3 weeks plus prednisone 5mg twice daily orally
Trial: 28903131
Drug: Fluorouracil-based adjuvant
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil-based adjuvant chemotherapy in MGMT-positive patients
Trial: 19698734
Drug: GVG (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVG (1 g/day increased to 5 g/day)
Trial: 15025222
Drug: Low-dose doxycycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxycycline (20 mg) b.i.d. for 3 months plus scaling and root planing (SRP)
Trial: 15025222
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules b.i.d. for 3 months plus scaling and root planing (SRP)
Trial: 11597949
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E at 300 mg/d during dinner (group B)
Trial: 11597949
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E at 300 mg/d on an empty stomach (group A)
Trial: 8624429
Drug: Nafarelin acetate
RxNorm normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate 600 micrograms/daily
Trial: 8624429
Drug: D-Trp6-LHRH 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Trp6-LHRH 0.5 mg/daily
Trial: 2722135
Drug: Oral fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fructose load
Trial: 141471
Drug: Aerosolized atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized atropine sulfate (1 mg)
Trial: 31871257
Drug: Dry cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry cupping therapy application with two suctions, performed once a week for 8 weeks.
Trial: 31871257
Drug: Placebo dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dry cupping therapy, performed once a week for 8 weeks.
Trial: 23986166
Drug: Test formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formula containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water applied twice daily for 4 weeks as monotherapy
Trial: 23986166
Drug: Test formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formula applied twice daily for 8 weeks as adjunctive therapy
Trial: 23986166
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied twice daily for 8 weeks
Trial: 21074790
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg desmopressin orally at bedtime
Trial: 15196307
Drug: Training module
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training module and administration of the guideline (Arm 1)
Trial: 15196307
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of guideline without training (Arm 2)
Trial: 11758228
Drug: Tpo levels
RxNorm normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tpo levels in CITP patients with glucocorticoid therapy response
Trial: 9127923
Drug: Epidural blockade
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blockade with 20 ml of 0.25% bupivacaine
Trial: 3284457
Drug: Ceftazidime (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (30 mg/kg)
Trial: 3284457
Drug: Cefoperazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (30 mg/kg)
Trial: 23216423
Drug: Betrixaban 80
RxNorm normalized name: betrixaban 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betrixaban 80 mg
Trial: 23216423
Drug: Betrixaban 140
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betrixaban 140 mg
Trial: 19238715
Drug: Kangaroo Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaroo Care (KC) for 10 min before the injection and during the procedure
Trial: 16572350
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (NE)
Trial: 12944340
Drug: Therapeutic effects
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic effects of treatment
Trial: 9211675
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of elemental calcium
Trial: 28682183
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use at baseline
Trial: 21302036
Drug: NIPRD-AM1 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPRD-AM1 (250 mg×2) with metronidazole (200 mg×2)
Trial: 21302036
Drug: Metronidazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (200 mg×2) alone
Trial: 17009630
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue treatment
Trial: 12657164
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus SU5416 (VEGF receptor tyrosine kinase inhibitor)
Trial: 6454395
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with 13‐cis retinoic acid
Trial: 30910894
Drug: DSTA4637S (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSTA4637S (5, 15, 50, 100, and 150 mg/kg)
Trial: 28328705
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 650 nm, administered every other day for 17 weeks
Trial: 25829373
Drug: Intravenous fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosfomycin (4 g/6 h)
Trial: 23949025
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy with sequential target presentation
Trial: 23949025
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy with random target presentation
Trial: 17655805
Drug: rTMS (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS (10 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Trial: 17655805
Drug: rTMS (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS (20 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Trial: 15175560
Drug: Terbutaline (large
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (large intravenous doses)
Trial: 11355926
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation treatment with high-dose Ara-C
Trial: 9935255
Drug: Trovafloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trovafloxacin (200 mg) with Morphine (0.15 mg/kg)
Trial: 1303534
Drug: Morphine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.15 mg/kg)
Trial: 9052509
Drug: Omeprazole therapy
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole therapy for eight weeks
Trial: 2476613
Drug: Controlled-release isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg once daily
Trial: 2476613
Drug: Controlled-release isosorbide-5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg twice daily
Trial: 786379
Drug: Oral papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral papaverine (300 mg b.i.d.)
Trial: 19308305
Drug: Natalizumab in
RxNorm normalized name: natalizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab in treatment-naive patients with highly active disease
Trial: 19308305
Drug: Natalizumab in
RxNorm normalized name: natalizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab in patients with highly active disease despite IFNbeta-1a treatment
Trial: 8350329
Drug: Leucovorin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin (1 mg)
Trial: 2871058
Drug: Clonidine, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine, 0.4 mg/day
Trial: 27000036
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation (eight weekly sessions)
Trial: 27000036
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (eight weekly sessions)
Trial: 24119199
Drug: CoQ10 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (200 mg/day)
Trial: 19419253
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor and diuretic combination
Trial: 7870011
Drug: HuEPO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuEPO treatment for anemia in preterm infants
Trial: 30392080
Drug: aPDT adjunct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aPDT adjunct to SRP
Trial: 21896619
Drug: Ordinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary treatment (Control)
Trial: 15369941
Drug: Pinch technique
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinch technique before and during DMPA injection
Trial: 15369941
Drug: Injection only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection only (control group)
Trial: 11600531
Drug: Tibolone 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 0.3 mg daily
Trial: 11600531
Drug: Tibolone 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 0.625 mg daily
Trial: 11600531
Drug: Tibolone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 1.25 mg daily
Trial: 2459988
Drug: Atracurium (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (dosage not specified)
Trial: 241119
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin stearate (500 mg twice or 3 times a day for 10 days)
Trial: 26144593
Drug: Cannabis-alcohol combination
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis-alcohol combination (5μg/L THC + 0.05g/210L alcohol)
Trial: 21401541
Drug: Ocular compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular compression using an external pressure device for 20 min before combined peri- and retrobulbar injection
Trial: 19336453
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg twice a day) plus optimized background therapy (OBT)
Trial: 17353499
Drug: High-fiber DASH
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber DASH diet (30 g/d)
Trial: 17353499
Drug: Fiber-supplemented diet
RxNorm normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber-supplemented diet (30 g/d)
Trial: 8172146
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. (group I; n = 35)
Trial: 8172146
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.i.d. plus amoxicillin 1 g b.i.d. (group II; n = 35)
Trial: 31661579
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with 12 weeks of education (I-group)